Molecular mechanisms of right ventricular dysfunction in pulmonary arterial hypertension: focus on the coronary vasculature, sex hormones, and glucose/lipid metabolism

Vineet Agrawal¹, Tim Lahm², Georg Hansmann³, Anna R. Hemnes⁴

¹Division of Cardiology, Department of Medicine, Vanderbilt University Medical Center, Nashville, TN, USA; ²Department of Medicine, Indiana University, Indianapolis, IN, USA; ³Department of Pediatric Cardiology and Critical Care, Hannover Medical School, Hannover, Germany; ⁴Division of Allergy, Pulmonology and Critical Care, Department of Medicine, Vanderbilt University Medical Center, Nashville, TN, USA

Contributions: (I) Conception and design: All authors; (II) Administrative support: None; (III) Provision of study materials or patients: None; (IV) Collection and assembly of data: All authors; (V) Data analysis and interpretation: All authors; (VI) Manuscript writing: All authors; (VII) Final approval of manuscript: All authors.

Correspondence to: Vineet Agrawal, MD, PhD. Division of Cardiology, Department of Medicine, Vanderbilt University Medical Center, 2220 Pierce Ave., 383 Preston Research Building, Nashville 37232-6300, TN, USA. Email: vineet.agrawal@vumc.org.

Abstract: Pulmonary arterial hypertension (PAH) is a rare, life-threatening condition characterized by dysregulated metabolism, pulmonary vascular remodeling, and loss of pulmonary vascular cross-sectional area due to a variety of etiologies. Right ventricular (RV) dysfunction in PAH is a critical mediator of both long-term morbidity and mortality. While combinatory oral pharmacotherapy and/or intravenous prostacyclin aimed at decreasing pulmonary vascular resistance (PVR) have improved clinical outcomes, there are currently no treatments that directly address RV failure in PAH. This is, in part, due to the incomplete understanding of the pathogenesis of RV dysfunction in PAH. The purpose of this review is to discuss the current understanding of key molecular mechanisms that cause, contribute and/or sustain RV dysfunction, with a special focus on pathways that either have led to or have the potential to lead to clinical therapeutic intervention. Specifically, this review discusses the mechanisms by which vessel loss and dysfunctional angiogenesis, sex hormones, and metabolic derangements in PAH directly contribute to RV dysfunction. Finally, this review discusses limitations and future areas of investigation that may lead to novel understanding and therapeutic interventions for RV dysfunction in PAH.

Keywords: Pulmonary arterial hypertension (PAH); right ventricular failure (RV failure); sex hormones; metabolism; coronary vasculature

Introduction

While the pathobiology of pulmonary arterial hypertension (PAH) is complex and incompletely understood, common features of all presentations include a substantial increase in pulmonary vascular resistance (PVR) due to pulmonary vascular remodeling and a concomitant right ventricular (RV) remodeling (1). Notably, among these two manifestations, RV dysfunction (RVD) and RV failure are the major determinants of morbidity and mortality in patients with PAH, in part due to therapeutic advances in improving PVR (2,3). While RV function can significantly be affected by both preload (volume, pressure) and afterload (pressure) conditions in PAH (4), recent evidence suggests that RV dysfunction may occur independent of the loading conditions in PAH. Despite many therapeutic advances in left heart failure, comparatively less is understood regarding the pathobiology of RV dysfunction (5,6).

Studies investigating RV dysfunction in the setting
of PAH have characterized both adaptive/hypertrophic responses to pressure afterload as well as maladaptive responses such as dilation and pump dysfunction that ultimately lead to clinical heart failure (7). Major factors that have been implicated in maladaptive remodeling of the RV include increased pressure afterload, myocardial hypoxia, and metabolic dysfunction.

A combination of genetic predisposition and initiating/driving factors such as inflammation, drugs, infections, and sex hormones ultimately results in adverse pulmonary vascular and cardiac remodeling (8-12). This combination of factors ultimately initiates and perpetuates the vicious cycle of RV failure through increased pressure afterload, myocardial hypoxia, and metabolic dysfunction (Figure 1).

The focus of this review is on the molecular mechanisms that may contribute to maladaptive remodeling in the RV. Although many pathways are currently under study in the pathogenesis of RV failure (13-15), this review will specifically focus on select molecular events and pathways that are supported by strong pre-clinical and human (clinical) data that have resulted in, or will lead to, clinical trials in PAH patients.

**Dysfunctional coronary artery and capillary formation/angiogenesis**

**Micro- and macro-vascular malperfusion/ischemia**

Coronary blood flow and adequate tissue perfusion is thought to be an important component of the myocardium’s response to increased workload and hypertrophy in PAH (16-21). Emerging evidence suggests the involvement of macro- and micro-vascular ischemia in the development of RV failure (Figure 2). The combination of increased RV mass, increased RV workload, and coronary flow impairment causes a significant supply-demand discrepancy (19-21), ultimately leading to maladaptive RV remodeling. Malperfusion/ischemia, and concurrent metabolic changes (outlined later in this review), in the cardiomyocyte are thought to give rise to what is referred to as hibernating myocardium (22). A detailed discussion of the phenotype of hibernating myocytes is beyond the scope of this review, but nicely reviewed elsewhere (22). Notably, mechanisms underlying hibernating myocardium have predominantly been studied in the left ventricle, and considerably less is understood about the pathophysiology of hibernation in the RV. This review will focus on the mechanisms by which coronary macro- and micro-vasculature are altered to ultimately lead to RV failure.

The normotensive RV is perfused during both systole and diastole, and in most instances via the right coronary artery (RCA) arising from the right coronary cusp of the aortic root (23). With systemic or suprasystemic RV pressure, the RV myocardium is only perfused during diastole, making the blood supply more dependent on lower heart rates and filling time. Moreover, increased RV end-diastolic pressure (RVEDP) and a thick RV myocardium decrease coronary perfusion pressure and flow to the RV myocardium. As demonstrated by non-invasive myocardial perfusion reserve measurement through adenosine challenge, in severe or advanced PAH, there is decreased perfusion reserve in the RV (24). This was more directly demonstrated in a human MRI-based study by van Wolferen et al. that showed both systolic and diastolic flow in the RCA of normal controls, but diastole-predominant flow in the RCA of patients with PAH with an overall decrease in total blood flow to the RV (23). Histologically, post-mortem human and animal model studies have shown increased thickness of epicardial arteries in PAH (25). While layer-specific (e.g., intima, media, or adventitia) changes were not delineated, increased α-SMA staining, IL-6 mRNA, DNA damage, and pro-inflammatory epigenetic modifier BRD4 were found in arteries from PAH patients, suggesting inflammation and smooth muscle hyperplasia as important contributors to coronary remodeling (25).

**The role of microvascular ischemia in RV failure**

In addition to the large epicardial arterial changes noted above, studies have suggested prominent microvascular changes in the RV in PAH, similar to established studies of microvascular rarefaction and dysfunction in left ventricular (LV) failure (16-18,26,27). Indeed, using traditional two-dimensional sections, several studies identified vascular rarefaction in models of RV failure (28-34). In contrast, models of compensated RV hypertrophy [chronic hypoxia, mild pulmonary artery banding (PAB)] demonstrated maintained or increased angiogenesis (28,29,35,36), suggesting a mechanistic link between microvascular density/function and RV failure development. While it is not clear whether microvascular dysfunction is merely a marker of or a contributor to RV failure, experimental approaches to improve RV vasculization through therapies such as delivery of miR-126 in an experimental model of PH have demonstrated increased RV vascularity/function without changes in the pulmonary vasculature,
Figure 1 The vicious cycle of RV failure in PAH. In the setting of underlying genetic predispositions, initiating or modifying factors such as drugs, inflammation, infection, and/or sex hormones begin the vicious cycle of RV failure either through direct action upon the RV (via altered metabolism or transcriptional regulation), or secondarily through increased PVR and RV ischemia. RV, right ventricular; PAH, pulmonary arterial hypertension; PVR, pulmonary vascular resistance; RVSP, right ventricular systolic pressure.

Figure 2 Schematic diagram of mechanisms underlying dysfunctional angiogenesis in the progression from adaptive RV hypertrophy to maladaptive RV failure in PAH. RV, right ventricular; PAH, pulmonary arterial hypertension.

suggesting a more causal role for microvascular dysfunction in the pathogenesis of RV failure (28). However, the translation of these pre-clinical findings to humans remains an area of ongoing investigation. A recent study of post-mortem human RV from female PAH patients employed a stereological approach to measuring vascularity and reported an increase in total vascular length in PAH (37) without signs of hypoxia or ischemia [contradicting previous investigations (38,39)]. Given the multiple discrepancies between these studies (method of measurement of
vascularity, appropriate determination of RV adaptation vs. failure in the human samples, possible sex-based effect, patient age, etc.), further work is necessary to clarify these findings.

Molecular mediators of angiogenesis in RV failure

The pathways and processes regulating angiogenesis are complex and many. Factors such as sex, age, severity of PH, disease stage, and other inter-related processes (metabolic dysfunction, inflammation) complicate and confound clear study of angiogenic mechanisms in the RV of PAH patients. However, growing evidence from both experimental models and human samples suggests dysregulation of angiogenesis in RV failure. Experimentally, studies have suggested a genetic component to RV adaptation in PH based on differing degrees of RV adaptation to the same afterload in two different strains of rat (Fischer vs. Sprague Dawley) (33). Epigenetically, Reddy et al. identified microRNAs uniquely associated with RV failure that mediate increased vascular tone (miR-143/145), enhanced apoptosis (miR-34), and decreased endothelial cell proliferation (miR-379, miR-503) (40). Chouvarine et al. identified transpulmonary changes in microRNAs, one of which has been implicated in vascular smooth muscle proliferation (miR-331-3p) (41). Beyond epigenetic changes, inter- and intra-cellular signaling through transcription factors, growth factors, hormones, peptides, and immune cells have also been implicated as mediators of angiogenesis in the RV. These pathways are extensively reviewed elsewhere (42). Of these pathways, the most extensively studied parameters are those of the vascular endothelial growth factor (VEGF) pathway. In general, VEGF signaling is increased or maintained in adaptive RV hypertrophy (30,32,35), whereas VEGF signaling or receptor expression are downregulated in advanced RV failure (29-33,43). The previously mentioned decrease in miR-126 noted by Potus et al. (28) was associated with increased sprouty-related EVH1 domain-containing protein 1 (SPRED-1) which resulted in decreased activation of RAF and MAPK and inhibition of the VEGF pathway. Other pathways and modifiers found to be downregulated or impaired in experimental PH with maladaptive RV remodeling and failure include hypoxia-inducible factor (HIF) 1α (29,43), apelin (30), angiopoietin 1 (30), insulin growth factor 1 (30), and stromal derived factor 1 (43). The study of failing Fischer rat RVs revealed a decrease in expression of several angiogenic genes such as Angpt1 and Vegfc (33). On the other hand, the HIF inhibitor p53 was found to be upregulated in one model (43). A recent study reported a surprising role of regulatory T cells in increasing vasoprotective mediators in human microvascular cardiac endothelial cells (44). Studies specifically studying RV dysfunction in the setting of experimentally induced PAH through treatment with hypoxia and Sugen-mediated VEGF inhibition identified unique alterations in a number of genes related to angiogenesis in the RV of mice with RV failure, but not controls (34). Finally, emerging mediators of angiogenesis in the RV in PAH include molecules with potent angiostatic properties such as endostatin that are upregulated in plasma from PAH patients, but have not directly been studied in the RV (45).

Ultimately, it is not clear whether directly modifying angiogenesis in the RV may be beneficial or not. Several therapeutic strategies have been associated with increased RV vascularization or increased expression of pro-angiogenic mediators. These therapies include carvedilol (46), 17β-estradiol (47,48), genistein (49), dehydroepiandrosterone (50), exercise training (which increases RV capillarization in stable but not progressive PH) (51), protandim (29), prostacyclin (52), cardiotrophin 1 (53), PPARγ agonists (34), and miR-126 mimic (28). With the exception of miR-126 mimic, which restored RV vascularization and function without affecting pulmonary vasculature, all other therapies have been tested in experimental models of PH where direct effects on RV cannot be separated from reduced afterload due to effects on pulmonary vasculature. Further studies are needed to further delineate the role and regulation of angiogenesis in RV failure (54).

Sex hormones and their effect on RV function

Cardiomyocytes and other cells found in the heart (e.g., endothelial cells and fibroblasts) contain receptors for all major sex hormones (reviewed previously) (55,56). They also exhibit the machinery required for local sex hormone production and metabolism (48,57,58). It therefore is not surprising that sex steroids have emerged as important modifiers of RV structure and function in PAH. This section will review the currently available knowledge of the interplay between sex steroids and RV adaptation in preclinical and clinical studies (Figure 3).

Although PAH has long been known to be a female-predominant disease, studies have identified that females with PAH exhibit better survival than male counterparts (59-63). Females with PAH also exhibit improved RV
function, even after adjustment for age, body weight, and LV function (64-66). Better RV function in females has been shown to account for a significant component of the survival advantage that has been noted in previous epidemiologic studies (63). Notably, these findings have also now been verified in other groups of patients with non-PAH types of PH (e.g., Group 2 and 3 PH) (67-69).

Several lines of evidence indicate that sex hormones may, in part, account for the sex-specific differences noted in RV function. In healthy individuals without PAH in the MESA-RV cohort, post-menopausal hormone therapy users exhibited higher RV ejection fraction (RVEF) than non-users (70). In hormone therapy users, plasma levels of 17β-estradiol (E2) correlated with higher RVEF and lower RV end-diastolic volumes. Other studies of the MESA-RV cohort have found that higher DHEA plasma levels are associated with lower RVEF, higher RV stroke volume, and larger RV mass/volume (70). Finally, studies have demonstrated that single nucleotide variants that modulate the function of estrogen metabolism such as cytochrome P450 1B1 (CYP1B1) and androgen receptor (AR) are associated with changes in RV structure/function in normal patients, suggesting a direct role for sex-hormone mediated modification of RV size/function (71).

The roles of estrogen and DHEA in modifying RV function have been replicated indirectly in a cohort of PAH patients as well. Females younger than age 45 exhibited higher cardiac index than male counterparts (66). However, this difference dissipated after 45 years of age, suggesting that sex hormones are a potential modifier of RV adaptation in PAH. Additionally, in post-menopausal women with PAH, lower DHEA levels were associated with increased RV dilation and worse function by echocardiogram (72). Given the dual roles of sex hormones upon myocardial and pulmonary vascular function, though, these studies cannot distinguish whether the observed associations were due to primary effects on the RV as opposed to indirect changes as a result of modulation of RV afterload.

Several studies have now investigated the therapeutic potential of modulating the sex hormone axis (Figure 3) in regulating RV function in models of PAH. Interestingly, while estrogen E2 or its metabolites are thought to promote adverse pulmonary vascular remodeling (73), E2 has been shown to exhibit RV-protective effects in vivo. Through hormone depletion and repletion studies in a rat model of Sugen/hypoxia, Frump et al. demonstrated that E2 attenuates RV hypertrophy, improves cardiac index, and enhances exercise capacity (48). The presence of E2 results in decreased RV apoptotic signaling, pro-inflammatory cytokine expression, oxidative stress, and mitochondrial dysfunction (48). Additionally, E2 attenuated decreases in pro-angiogenic and pro-contractile expression of apelin,

Figure 3 Sex hormone synthesis pathways with known effects of intermediates upon pulmonary vascular and RV cardiomyocyte remodeling. RV, right ventricular.
suggesting a role for E2 in angiogenesis (48). Importantly, protective effects of E2 were noted in ovariectomized female rats as well as in male rats. In a follow-up study in SuHx rats, E2 attenuated RV dysfunction induced by a bout of acute strenuous exercise; these effects were accompanied by increased eNOS activation and enhanced autophagic flux in the RV (74). This study also demonstrated anti-fibrotic effects of E2. Anti-fibrotic effects were also observed in the SuHx-PH mouse model (75), even though it should be noted that this model only exhibits mild RV dysfunction (54). The same group of investigators also reported beneficial effects on mitochondrial function in the RV with E2 treatment (76). A study performed in the monocrotaline rat model suggested pro-angiogenic effects of E2 (47). While that study suggested estrogen receptor β as a mediator of protective E2 effects in the RV, the previously mentioned study in SuHx-PH rats (48) implicated estrogen receptor α as a mediator of E2 protection. The reasons for this discrepancy are unclear, but may include differences between models, sex-specific effects or off-target effects of pharmacological inhibitors and activators. In addition, E2 also affects mechanical properties of the pulmonary vasculature which in turn could affect RV structure and performance. In particular, E2 can increase both proximal as well as distal PA compliance, and, at least when given exogenously, also attenuate PA remodeling (75,77,78). It is currently unknown if E2's RV-protective effects are mediated by direct effects on RV-specific cell types or by more indirect effects resulting from reducing RV afterload. Studies employing PAB and investigating E2 signaling in RV-specific cell types (cardiomyocytes, endothelial cells and fibroblasts) will address this knowledge gap.

In addition to estrogen, testosterone and DHEA signaling have also been studied in the RV. While testosterone was associated with worse RV function and fibrosis in a pulmonary banding model (79), DHEA was found to attenuate RV capillary rarefaction, apoptosis, fibrosis, and oxidative stress in Sugen/hypoxia treated rats. This was at least partially mediated by reducing expression/activity of Rho kinases, STAT3, and NFATc3 (50). Direct study of cardiomyocytes in vitro has demonstrated that DHEA reduces endothelin-1 induced hypertrophy and natriuretic peptide expression (80). With aldosterone or corticosteroid stimulation, DHEA decreases T-type calcium channel expression and exhibits anti-hypertrophic/chronotropic effects (81). Unlike E2, however, DHEA has not been associated with adverse pulmonary vascular remodeling, making this an attractive target for hormone-based therapies for RV failure.

While no clinical studies to date have directly used hormone-based therapies to improve RV failure in PAH, there is a growing interest in these pathways given pre-clinical benefit from E2 and DHEA. In particular, there are two trials currently investigating the effect of estrogen inhibition on PAH development (NCT03229499, NCT03528902), based on the known association between E2 levels and adverse pulmonary vascular remodeling (72,73,82). Given concerns regarding potential direct detrimental effects on RV function (83), and despite relatively neutral effects upon the RV in pilot studies (84,85), both ongoing trials are closely monitoring RV function in their participants. Ultimately, due to E2's pleiotropic effects, more specific or downstream approaches may be necessary to maximize the benefits and limit the harms of modulating estrogen therapies in PAH. Therapy with DHEA may be a more straightforward target based on its beneficial effect upon RV function in the absence of detrimental effects upon pulmonary vasculature. A study investigating DHEA supplementation in PAH is currently ongoing and will assess RV function and structure by cardiac MRI (NCT03648385).

**Metabolic derangements in RV hypertrophy, dilation and failure**

Cellular metabolism comprises a ubiquitous set of pathways that continually maintain cellular homeostasis through modulation of energy production, synthesis of components, breakdown of waste, and ultimately cell survival. These pathways are particularly relevant in high energy utilizing tissues such as the heart. Despite the known differences in embryologic origin, baseline expression, and loading conditions of the right and left ventricle (5,7,86,87), the majority of studies investigating RV metabolism are based on metabolic investigations in the LV (88). Under basal conditions, the RV generates ATP primarily from fatty acids (~70%) with a smaller percentage from uncoupled glycolysis or lactate utilization (89). However, in various situations, the myocardium is able to generate ATP from any of a number of sources including fatty acids, glucose, lactate, ketones, and amino acids, demonstrating metabolic plasticity (90-93). Stresses such as increased load on the RV or ischemia can drive changes in the uptake, generation, transport, storage and utilization of preferred substrate for energy generation (5).

Studies of pulmonary vascular endothelial cells from patients with PAH have identified metabolic shifts in PAH...
that mirror metabolic changes in malignancy (7). In PAH, these metabolic shifts in cardiovascular cells include an increased preference for aerobic glycolysis (known as the Warburg effect) (94), impaired mitochondrial respiration due to decreased fatty acid oxidation (95,96), and increased utilization of glutamine in the Krebs cycle for biosynthesis and proliferation (97). The mechanisms by which each of these pathways affects myocardial function, and potential avenues for therapeutic intervention, are discussed below (Figure 4).

Mitochondrial dysfunction in the RV in PAH

Mitochondria are the intracellular site for many important metabolic pathways including oxidative phosphorylation, Krebs cycle, \( \beta \) oxidation of fatty acids, calcium handling, free radical handling, and heme synthesis. It is thus not surprising that mitochondrial dysfunction is thought to play a central role in PAH-related metabolic reprogramming (98,99). Mitochondrial morphology is intimately connected with the overall metabolic state of a cell (100). This is particularly true in a high energy utilizing cell such as the cardiomyocyte where mitochondria account for nearly 90% of the ATP generation and 30% of the overall cell mass (101).

Mitochondrial dysfunction has been shown to play a central role in the progression of left heart failure (102). However, preclinical studies of RV failure in the setting of PAH have also demonstrated a decrease in intact mitochondria (31,34,103,104). Legchenko et al. (34), showed that SuGen/hypoxia exposed rats developed RV hypertrophy and dilation 6 weeks after the end of hypoxia. By applying comprehensive electron microscopy studies, Legchenko et al. demonstrated increased variability in mitochondrial size, mitochondrial disarray, decreased mean mitochondrial diameter, and an increased number of autophagosomes near mitochondria, all suggesting dysregulation of mitochondrial morphology and function (mito dynamics) (34).

Importantly, the detrimental structural changes and dysfunction of mitochondria are associated with decreased expression of metabolic master regulators such as PPAR\( \gamma \) (105), PPAR\( \gamma \) coactivator (PGC1\( \alpha \)) (103), and PPAR\( \alpha \) (103). These three metabolic master regulators have key functions in myocardial function, particularly in the setting of RV pressure overload associated with PAH. In particular, targeted deletion of PPAR\( \gamma \) in cardiomyocytes in mice, in the absence of PAH, led to biventricular systolic dysfunction, suggesting a direct role for modulating cardiomyopathy even in the absence of an increased RV afterload (34).

The PPAR \( \gamma \) agonist pioglitazone reverses pulmonary arterial hypertension and prevents right heart failure in the SuHx rat model via fatty acid oxidation and induction of key genes such as CPT1b and FABP4 (34). The major

---

Figure 4 Summary of metabolic derangements identified in RV cardiomyocytes in PAH. Solid arrows denote pathways increased in PAH, and dashed arrows represent pathways decreased in PAH. RV, right ventricular; PAH, pulmonary arterial hypertension.
transcriptional epigenetic pathogenic findings of this study in SuHx rats could be recapitated in human end-stage PAH (34): (I) in the pressure-overloaded failing RV (miR-197 and miR-146b up-regulated; CPT1B and FABP4 downregulated), (II) in peripheral pulmonary arteries (miR-146b up-regulated, miR-133b down-regulated), and (III) in plexiform vasculopathy (miR-133b up-regulated, miR-146b down-regulated) (34).

The mechanisms that lead to decreased mitochondrial mass are incompletely understood, but have been thought to be related to imbalances in mitochondrial fission/fusion and mitophagy (99,106,107). Mitochondria are dynamic organelles that organize in networks to coordinate cell-wide metabolic function (98). As such, mitochondria exist in a constant state of flux. They undergo fission and fusion as they adapt to the needs of the cell, with surplus or mitochondria undergoing mitophagy to maintain the mitochondrial network integrity. Dynamin-like GTPases knowns as mitofusins (MFN1 and MFN2) mediate fusion of mitochondria. Conversely, dynamin-related proteins (Drp1) complexes with mitochondrial fission protein 1 (Fis1) on the outer membrane of mitochondria to regulate fission. Studies of human pulmonary artery (PA) smooth muscle cells from patients with PAH have demonstrated increased fragmentation of mitochondria and increased mRNA expression of fissiogenic molecules (Drp1, Fis1). The presence of activated Drp1 has also been demonstrated in the pulmonary vasculature in fixed tissue sections of patients with PAH (108). Pre-clinical models of PAH using monocrotaline induced vascular damage have also confirmed increased expression of Drp1 in the right ventricle of rats with PAH (108).

**Glycolytic pathways and pyruvate**

While the RV normally preferentially metabolizes free fatty acids to generate ATP through oxidative phosphorylation (89), ischemia and pressure afterload on the RV result in a shift from fatty acid oxidation towards increased reliance on glucose for ATP generation (109,110). Specifically, glucose utilization largely shifts towards the glycolytic pathway and away from the Krebs cycle (111). This shift occurs despite the adequate availability of oxygen to undergo oxidative phosphorylation, a phenomenon known as the Warburg effect, and ultimately decreases the efficiency of ATP generation by reducing utilization of mitochondrial oxidative metabolic pathways. Both pre-clinical and clinical studies have demonstrated the importance of pyruvate dehydrogenase kinase (PDK) in mediating the shift towards aerobic glycolysis in PAH (112,113). PDK is a key inhibitor of pyruvate dehydrogenase, and therefore an inhibitor of glucose oxidation. Studies have shown a marked increase in the expression of PDK isoforms in patients with PAH, with the predominant cardiac isoforms consisting of PDK2 and PDK4. Preferential switch towards glycolysis is associated with decreased RV contractility. In pre-clinical models, pharmacologic inhibition of PDK results in improved RV contractility (Figure 5) (112). Recently, in a clinical study of patients with PAH without clinical improvement on standard therapies, pharmacologic inhibition of PDK with a small molecular inhibitor, dichloroacetate (DCA), resulted in decreases in mean PA pressure, decrease in PVR, and increase in cardiac output (CO). Interestingly, response to DCA was stratified by the presence or absence of common genetic variants in two genes known to alter baseline PDK activity independently, sirtuin 3 and uncoupled protein 2. Beyond altering PDK activity, recent studies have also shown that sirtuin 3 may itself be a master regulator of metabolism in PAH, suggesting that a subset of patients with PAH may be more likely to derive benefit from metabolic therapies (97,114). However, considering both the subset of patients more likely to respond to therapy as well as identification of potential severe neurotoxicity as a result of PDK inhibition by DCA (115,116), the ultimate translatability of PDK inhibition may require precision medicine approaches to define the subset of patients most likely to benefit and least likely to experience side effects.

**Dysfunctional fatty acid metabolism and lipotoxicity**

Previous studies have also consistently found that the RV of patients with PAH demonstrates significant decreases in fatty acid oxidation compared to patients without PAH (5,7). Other studies have demonstrated an increase in lipid accumulation in the RV myocardium of patients with PAH (12,95). While the mechanisms underlying this observation are incompletely understood, multiple mechanisms have been identified that contribute both to decreased fatty acid oxidation and cytoplasmic lipid accumulation. Impairment of fatty acid oxidation, concomitant with increased fatty acid uptake, enable the production of toxic intermediates such as ceramide, palmitate, and medium and long chain fatty acids (12,91,96,117). The above intermediates most likely lead to lipotoxic cardiomyopathy, for example, via...
excessive development of reactive oxygen species and cell apoptosis (118).

Derangements in fatty acid oxidation and toxic lipid accumulation are thought to occur as a result of multiple mechanisms. The first is an increase in the uptake of fatty acids into the myocardium. Fatty acid binding proteins and CD36 are thought to be the primary receptors responsible for transporting fatty acids into the cytoplasm of cells, with CD36 being responsible for ~60% of fatty acid uptake (119,120). Pre-clinical studies in a model of BMPR2 mutation related PAH have demonstrated an increase in the expression of CD36 in the RV of mice that develop PAH (12). Additionally, increased circulating levels of heart-specific fatty acid binding protein have been found to be an independent predictor of adverse outcomes in patients with chronic thromboembolic pulmonary hypertension (PH) (121).

The second mechanism thought to contribute to this accumulation of lipids in cardiomyocytes is the finding that the RV in PAH is characterized by a decrease in mitochondrial utilization of fatty acids compared to healthy controls (5,95,122). This phenomenon, while incompletely understood, is postulated to be regulated transcriptionally and metabolically. Transcriptional regulation occurs through the noted downregulation of key modulators and inducers of mitochondrial fatty acid oxidation, PPARγ and PGC1α (103). Metabolic regulation has been proposed to occur through the Randle Cycle (5,123), a metabolic process in which glucose and fatty acids counter-regulate each other by directly competing as substrates for ATP generation within a given cell. While previous studies have suggested that a further shift away from fatty acid oxidation towards glucose oxidation through the Randle cycle will reduce oxygen consumption by ~12% per ATP molecule generated (5), recent studies suggest that a shift from fatty acid to glucose oxidation ultimately results in less efficient ATP production and ultimately promotes hibernation of myocardium (34). The mechanical complications of hibernating myocardium have been reviewed elsewhere (22).

A recent study by Chouvarine et al. has also demonstrated accumulation of dicarboxylic acids and acylcarnitines trans-RV gradients, suggesting a block in β-fatty acid oxidation (41). The identified trans-RV and transpulmonary metabolite gradients also correlate with hemodynamics, further supporting a functional consequence of the identified metabolic changes.

Thus, there are currently alternative approaches aimed directly at addressing the deficit in fatty acid oxidation with a goal of normalizing the RV metabolic pattern. One approach has involved the use of therapies aimed at activating PPARγ, a key modulator of fatty acid oxidation. Pre-clinical trials investigating the efficacy of PPARγ agonists have demonstrated that increasing fatty acid oxidation can prevent the development of RV failure in a model of endothelial injury and hypoxia mediated PAH and RV failure (Figure 5) (34). Another approach that is currently undergoing pre-clinical and clinical investigation is the use of metformin to reverse deficits in fatty acid oxidation (Figure 5). Multiple pre-clinical models of both PAH and PH due to heart failure have demonstrated a potential beneficial role for metformin in both decreases in RV lipid accumulation as well as reversal of pulmonary vascular remodeling (96,124,125). Clinical trials are currently ongoing that will be directly assess the potential benefit of metformin on both clinical outcomes and RV function (NCT 01884051 and NCT03617458). Metformin's function is thought to be pleiotropic, but thought to involve at least the activation of AMP kinase (and downstream decrease in fatty acid synthesis and increase in insulin sensitivity) as well as non-AMPK mediated inhibition of adenylyl cyclase to ultimately promote decreased gluconeogenesis and increased glycolytic activity (96,126,127). Finally, although limited to a single center, a clinical study in a select population of patients with β-thalassemia and PH demonstrated that oral administration of L-carnitine significantly reduced pulmonary pressures (128). While the mechanisms underlying this phenomenon are not clear, L-carnitine serves as a shuttle for long-chain fatty acids to be transported to the mitochondria to undergo β oxidation, again suggesting that restoring fatty acid oxidation may be valuable.

**Insulin resistance and dyslipidemia in PAH-related RV dysfunction**

Although insulin resistance is known to be a primary contributor systemic arteriovascular disease, studies have also shown a higher than expected prevalence of insulin resistance in patients with PAH (129-134). The known alterations in glucose and fatty acid oxidation ultimately contribute to mitochondrial dysfunction, a key driver of insulin resistance in multiple cell types (135). In addition to stimulating increased glucose uptake and fatty acid oxidation, insulin plays an important role of modulating lipid homeostasis by modulating lipolysis and free fatty acid delivery between adipose and liver tissues (136). While...
insulin resistance has been shown to be a contributor to pathologic pulmonary vascular remodeling in multiple pre-clinical models of PAH (129,130,133,134,137), recent studies have also demonstrated a key role for insulin in altering RV function in humans as well. In vitro, recent studies have demonstrated a causal role for BMPR2 in maintaining insulin signaling and glucose homeostasis in cardiomyocyte-like cells (138). Studies in human RV and LV also suggest that the RV may be more prone to changes in insulin-related signaling. RNA sequencing analysis of healthy human RV and LV demonstrated an increase in transcripts associated with insulin signaling in the RV (139). Additionally, patients with diabetes but without PAH (and therefore no significant afterload) consistently demonstrate decreases in indices of RV function non-invasively (140-142). Finally, the presence of metabolic syndrome, and not obesity alone, is associated with a load-dependent decrease in RV function, suggesting a loss of contractile reserve in the setting of insulin resistance (143). Most recently, Mey et al. have utilized a hyperglycemic clamp in patients with PAH and controls to demonstrate global alterations in glucose homeostasis with a reduced response of insulin response to hyperglycemia (144). More importantly, their work suggested compartmental changes in insulin sensitivity, with increased insulin sensitivity in the skeletal muscle despite a decreased insulin response to hyperglycemia. While their study cannot directly comment on myocardial insulin sensitivity, their study corroborates previous studies confirming an important and direct role for insulin signaling in the pathogenesis of PAH (129,131,144).

Glutaminolysis

It is known that both the pulmonary endothelium and right
ventricle shift towards increased utilization of glutamine in patients with PAH (97). Glutamine is transported into the cell and converted into α-ketoglutarate by glutamate dehydrogenase. α-ketoglutarate is then fed into the Krebs cycle where its byproducts contribute to synthesis of amino acids, purines, pyrimidines, fatty acids, and sterols. While these byproducts are thought to contribute to increased cell growth and proliferation in cancer cells (145), its role in post-mitotic tissues such as the RV are less understood. In the pre-clinical model of monocrotaline-induced PAH and RV failure in rats, increased utilization of glutamine as well as increased expression of glutamine transporters was identified in the RV of rodents that developed PAH (31). Immunostains of post-mortem RV from patients with PAH also suggested an increase in sarcolemmal glutamine transporter expression, suggesting that glutaminolysis may be an important therapeutic target in RV failure due to PAH. Given the paucity of studies investigating this mechanism of altered metabolism in the RV, however, future studies are necessary to better elucidate the pathogenic role of glutaminolysis in RV failure.

Limitations and future approaches to understanding of molecular mechanisms underlying human RV failure

Pathophysiologic mechanisms contributing to RV failure in the setting of PAH have largely relied on pre-clinical studies in which careful manipulation, both genetic and therapeutic, are possible to tease out potential mechanisms. As reviewed by Stenmark et al., though, no current animal model of PAH perfectly recapitulates all features of the human disease (146). Additionally, this special issue also extensively discusses the strengths and weaknesses of various animal models of RV failure elsewhere (147). The study of RV failure in human subjects at the molecular level is inherently limited by the availability and quality of tissues available from patients, often post-mortem or at end stage. Additionally, modalities of study are often limited by methods of tissue preservation that have been applied such as formalin fixation and paraffin embedding. While modalities such as cardiac MRI have significant improved resolution in the measurement of RV size and function (63), specific studies of molecular pathways or targets are inherently limited in current non-invasive assessments of the RV in PAH. The role of imaging in RV failure and overall prognosis in PH is discussed elsewhere in this special issue (148-150).

Induced pluripotent stem (iPS) cells as an alternative to human tissue

While many previous studies have utilized isolated endothelial or PA smooth muscle cells for detailed in vitro studies, similar approaches are limited for study of the myocardium. In particular, cardiomyocytes are generally post-mitotic cells with very few studies successfully isolating and studying the myocytes themselves from human patients (8). The seminal finding by Takahashi and Yamanaka in 2006 that transfection of a defined set of transcription factors can convert differentiated cells into embryonic-like stem cells [induced pluripotent stem (iPS) cells] paved the way for tissue specific generation of various cell types from patient samples through transcription factor mediated generation of iPS cells. Previous groups have utilized this approach to begin to study the effect of known PAH-causing mutations in the BMPR2 gene upon endothelial and smooth muscle function (151-153). With significant advances in methods for generation of iPS derived cardiomyocytes (154), the pathogenesis of RV cardiomyopathy in the setting of either known mutations associated with PAH (i.e., BMPR2) or known patient populations who develop RV failure out of proportion to the degree of PH (i.e., systemic sclerosis) can be studied. With studies now demonstrating functional and molecular analyses in both single cells and engineered heart tissue constructs (155-157), as well as other studies beginning to identify protocols to specifically differentiate RV vs. LV cardiomyocytes (158), the use of iPS derived cardiomyocyte may shed light on to primary pathologic changes that occur in the myocardium in patients with PAH without the confounding variable of afterload (40,154,159).

Lessons learned from non-PAH related RV failure

While the current review has focused on mechanisms underlying RV failure in PAH, most patients with RV dysfunction suffer from PH due to other causes. Given the larger number of these group PH patients, directed study of these populations may provide further insight into the pathogenesis of RV failure in PAH as well. Indeed, at least a subset of patients with PH due to left heart disease (PH-LHD) display shared genetic architecture with PAH patients (160). Additionally, it is now recognized that a subset of patients with hemodynamics consistent with PAH at rest actually have occult diastolic dysfunction and resulting PH-LHD upon provocative challenge with
saline (161,162). Taken together there may, in fact, be some mechanistic overlap in the pathogenesis of RV failure among various groups of PH.

Similar to PAH, animal models of PH-LHD have also identified RV dysfunction as an early manifestation of disease (163). Exploiting common genetic variability among available mouse strains to identify genetically similar mice that were susceptible and resistant to high fat diet induced PH-LHD (164), a clearance receptor for natriuretic peptides (NPRC) was found to be the most differentially expressed gene in the RV of mice that developed PH-LHD. Natriuretic peptide levels also correlated with development of RV failure and PAH in a Sugen hypoxia model, and decreased in response to pioglitazone treatment (34). Finally, clinical studies have also demonstrated increased PVR in both pre-clinical and clinical models inversely correlated with levels of natriuretic peptides (165-168), altogether suggesting that natriuretic peptides and related pathways may be potential therapeutic targets in RV failure in PAH. Future studies are necessary to directly test this hypothesis, however.

Conclusions

RV failure continues to be the primary cause of morbidity and mortality in patients with PAH. In part due to fundamental differences between the LV and RV, and in part due to limitations in access to and ability to study human RV directly, the pathogenesis of maladaptive RV remodeling and resulting heart failure is incompletely understood. However, based on the breadth of pre-clinical and clinical studies to date, dysfunctional angiogenesis, sex hormone related biology, and fundamental shifts in cellular metabolism appear to play primary roles in the transition from adaptive to maladaptive remodeling of the RV. As pre-clinical studies continue to unravel the causal pathways that contribute to RV dysfunction in the setting of PAH, we look forward to future studies directly assessing the contributions of these pathways to RV failure in humans through both mechanistic and therapeutic studies.

Acknowledgments

Funding: NIH R01-HL144727-01A1 (TL), VA Merit Review Award 2 I01 BX002042 (TL), German Research Foundation DFG HA4348/2-2 and HA4348/6-2 (GH), and Federal Ministry of Education and Research BMBF ViP+ program-03VP08053; BMBF 01KC2001B (GH).

Footnote

Provenance and Peer Review: This article was commissioned by the Guest Editors (Martin Koestenberger, Harm-Jan Bogaard and Georg Hansmann) for the series “Right Ventricular Dysfunction” published in Cardiovascular Diagnosis and Therapy. The article was sent for external peer review organized by the Editor-in-Chief and the editorial office.

Conflicts of Interest: All authors have completed the ICMJE uniform disclosure form (available at http://dx.doi.org/10.21037/cdt-20-404). The series “Right Ventricular Dysfunction” was commissioned by the editorial office without any funding or sponsorship. GH served as the unpaid Guest Editors of the series. TL reports personal fees from Bayer, Inc., outside the submitted work. GH reports patent “Compositions and method for treatment of pulmonary hypertension”, 12/2009 USPTO application no. 1289344, Stanford University (Inventors: Georg Hansmann, Roham T. Zamanian, Marlene Rabinovitch). ARH reports personal fees from Actelion, personal fees from Bayer, personal fees from Complexa, personal fees from PHPrecisionMed, personal fees from united therapeutics, outside the submitted work. The author has no other conflicts of interest to declare.

Ethical Statement: The authors are accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved.

Open Access Statement: This is an Open Access article distributed in accordance with the Creative Commons Attribution-NonCommercial-NoDerivs 4.0 International License (CC BY-NC-ND 4.0), which permits the non-commercial replication and distribution of the article with the strict proviso that no changes or edits are made and the original work is properly cited (including links to both the formal publication through the relevant DOI and the license).
See: https://creativecommons.org/licenses/by-nc-nd/4.0/.

References


© Cardiovascular Diagnosis and Therapy. All rights reserved.


129. Hansmann G, Wagner RA, Schellong S, et al. Pulmonary...
arterial hypertension is linked to insulin resistance and reversed by peroxisome proliferator-activated receptor-gamma activation. Circulation 2007;115:1275-84.


1540

Cardiol 2018;114:320-7.

Cite this article as: Agrawal V, Lahm T, Hansmann G, Hemnes AR. Molecular mechanisms of right ventricular dysfunction in pulmonary arterial hypertension: focus on the coronary vasculature, sex hormones, and glucose/lipid metabolism. Cardiovasc Diagn Ther 2020;10(5):1522-1540. doi: 10.21037/cdt-20-404